Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · LYKALABS

LYKA LABS

HealthcarePharmaceuticals & Biotechnology₹322 cr market cap
₹91.58 ▲ +1.99% today As of 19 Nov 2026
52-week low ₹44.9552-week high ₹92.27

-2.7% from the 52-week high · +99.8% above the low

Lyka Labs Ltd. is a holding company, which engages in the manufacture of pharmaceutical formulations and active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra. The firm is focused on lyophilization - formulations/bulk sterile active pharmaceutical ingredients (APIs), and new product development including novel drug delivery systems in both topical preparation and lyophilized products. The firm manufactures pharmaceutical products, such as dry powder, liquid injections, lyophilized injections, ointment/creams and lotions, and external preparations for several international markets and the domestic market. The company offers formulations, such as emollient, anti-aging, cleansing lotion, hair care products, anti-dandruff shampoo, sunscreen, anti-acne, antioxidant tablets, antioxidants combination, proton pump inhibitor, anti-fungal, anti-malarial, anti-bacterial, corticosteroid hormones and cephalosporins. The firm's subsidiaries include Lyka BDR International Limited and Lyka Exports Limited.

The short version. LYKA LABS reported revenue of ₹44 crore for Sep 2026, up 18.9% from a year earlier. Net profit was ₹1 crore. Return on equity was -10.9% in Mar 2026. Promoter holding was 58.45% in Sep 2026, up 0.35 points over 8 quarters.

1 · The price

How has the stock traded?

LYKA LABS trades 2.7% below its 52-week high and 99.8% above its 52-week low.

Change over period: —

1M+4.4%
3M+26.9%
6M+48.0%
1Y+7.9%

2 · The business

Is it growing?

Sales, year on year+18.9%

Sep 2026 revenue of ₹44 cr.

Net margin2.9%

12.1 pts higher than a year earlier.

3-year growth-8.8% profit

Revenue compounded at 11.0% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue4442283137333334
Net profit12-80-3123
Net margin %2.94.9-27.1-0.5-9.23.05.38.0
EPS (₹)0.360.57-2.13-0.04-0.940.280.50.75

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue12813811193194866171
Net profit-108-3-1339-12-61-6
Net margin %-7.85.8-2.4-14.220.1-13.4-98.6-9.0
EPS (₹)-2.812.24-0.79-4.313.59-4.03-21.1-2.26

3 · The quality

How well does it turn capital into profit?

Return on equity was -10.9% in Mar 2026; debt to equity is 0.52.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %-10.97.7-3.8-29.1
Return on capital %-7.010.33.3-1.1
EBITDA margin %0.014.314.913.3
Net margin %-7.65.7-2.3-13.7

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR11.0%8.5%
Profit CAGR-8.8%-2.8%
Debt to equity0.52
Interest cover-2.5x
Current ratio1.17

4 · The owners

Who holds it, and are they adding?

Promoter holding58.45%

Up 0.35 pts over 8 quarters.

Foreign institutions0.15%

Unchanged over 8 quarters.

Domestic institutions0.66%

Down 0.01 pts over 8 quarters.

Mutual fund schemes0

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter58.158.1658.1658.1658.1658.1658.4558.45+0.35
FII0.150.230.160.180.170.290.170.150.0
DII0.670.670.670.670.670.670.660.66-0.01
Public41.0740.9441.0141.041.040.8840.7240.73-0.34

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for LYKA LABS are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about LYKA LABS

What is the LYKA LABS share price?

LYKA LABS (LYKALABS) last closed at ₹91.58, up 1.99% on the day. Its 52-week range is ₹44.95 to ₹92.27.

What is the market cap of LYKA LABS?

LYKA LABS has a market capitalisation of about ₹322 crore.

How are LYKA LABS's latest results?

LYKA LABS reported revenue of ₹44 crore for Sep 2026, up 18.9% from a year earlier. Net profit was ₹1 crore. Return on equity was -10.9% in Mar 2026. Promoter holding was 58.45% in Sep 2026, up 0.35 points over 8 quarters.

Who owns LYKA LABS?

As of Sep 2026, shareholding was: Promoter 58.45%, FII 0.15%, DII 0.66%, Public 40.73%.

How many mutual funds hold LYKA LABS?

0 mutual fund schemes held LYKA LABS in October 2026. That compares with 0 the month before.

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.